DDA Platform Delivers Tailored DMPK Services to Accelerate Drug Discovery and Development

December 24 21:24 2021
Creative Bioarray announced the launch of its professional DMPK services to help drug study design, data interpretation, study planning and execution.

New York, USA – December 24, 2021 – DDA Platform, the division of Creative Bioarray, is an innovative platform whose mission focuses on developing unique technologies and tailored products to promote research in drug discovery and development. With extensive industrial experience, Creative Bioarray is capable to accelerate the research progress in the field of pharmaceutical, biotechnology, agricultural, and diagnostics industries. Recently, Creative Bioarray announced the launch of its professional DMPK services to help drug study design, data interpretation, study planning, and execution.

The evaluation of DMPK can minimize the wastage rate of candidate drugs and improve the efficiency of overall drug discovery. Another benefit of DMPK research in the drug discovery and development process is that it allows chemists and analysts to achieve reasonable structural modifications, which can improve the pharmacokinetic properties and efficacy of drugs. At Creative Bioarray, the experienced DMPK department provides high-quality services and a wide range of standard in vitro and in vivo testing, covering the early detection stage and more advanced compound analysis. The expertise in this field also makes Creative Bioarray the best partner for the design and development of tailor-made in vitro or in vivo research.

The scientists at Creative Bioarray not only provide data, but also apply analysis experts to interpret the data to establish or modify the DMPK screening cascade. The fully validated analysis includes a wide range of physical and chemical analysis, in vitro ADME analysis, in vivo PK/PD and biological analysis, and toxicological analysis. Throughout the project process, customers will be able to access analysis data at any time to facilitate discussion and decision-making.

As a key aspect of drug development, Creative Bioarray is committed to seeking better use of PK/PD data to eliminate defective candidates from the beginning and identify those most likely to achieve clinical success. Understanding the bioavailability, exposure, half-life, clearance, and metabolism of a drug may determine clinical success or failure. Creative Bioarray provides in vivo PK/PD services, leveraging our extensive expertise and models to support drug discovery and preclinical development of small molecules, peptides, nucleosides/nucleotides, and biologics.

“We use the best screening equipment and cell models, as well as the latest innovations in drug discovery, to provide our customers with first-class results.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Creative Bioarray is capable of providing our customers with unique, high-quality, distinctive and tailor-made comprehensive drug discovery services.”

About DDA platform

As a mature division of Creative Bioarray, the DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerate drug development and improve research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://dda.creative-bioarray.com